With Health Care Reform In Doubt, Drug Pricing Remains Uncertain Too, Execs Note
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis, J&J execs question cost and pricing implications of health care reform in the aftermath of the Massachusetts special election.